The Ring System Is 4-aza-bicyclo(3.2.0)heptane (including Unsaturated) And Has Sulfur Bonded Directly At The 2-position Patents (Class 540/350)
-
Patent number: 7767809Abstract: The disclosed invention relates to a solvate of the compound (I) of the formula: or a crystal thereof.Type: GrantFiled: February 12, 2004Date of Patent: August 3, 2010Assignee: Shionogi & Co., Ltd.Inventor: Masaaki Uenaka
-
Publication number: 20100160284Abstract: The present invention provides ?-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of ?-methyl carbapenems which are useful as antibacterial agents.Type: ApplicationFiled: February 15, 2010Publication date: June 24, 2010Applicant: FOB Synthesis, Inc.,Inventors: Woo-Baeg Choi, Ewa Kowalk
-
Patent number: 7713573Abstract: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is placed on the surface of a medical device, then one component of the mixture or alloy is generally removed without generally removing the other components of the mixture or alloy. In some embodiments, a porous layer is adapted for bonding non-metallic coating, including drug eluting polymeric coatings. A porous layer may have a random pore structure or an oriented or directional grain porous structure. One embodiment of the invention relates to medical devices, including vascular stents, having at least one porous layer adapted to resist stenosis or cellular proliferation without requiring elution of therapeutic agents.Type: GrantFiled: February 10, 2006Date of Patent: May 11, 2010Assignee: Medtronic Vascular, Inc.Inventors: Gary K. Owens, Brian R. Wamhoff, Matthew S. Hudson, Whye-Kei Lye, Joshua Spradlin, Michael Reed, Kareen Looi
-
Patent number: 7687490Abstract: An objective of the present invention is to provide compounds that are effective against various resistant bacteria which cause current clinical problems, for example, pneumococci including penicillin resistant Streptococcus pneumoneae (PRSP), Haemophilus influenzae including bata-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella (Branhamella) catarrhalis.Type: GrantFiled: April 12, 2006Date of Patent: March 30, 2010Assignee: Meiji Seika Kaisha, Ltd.Inventors: Takahisa Maruyama, Yuko Kano, Takashi Ando, Takehiko Sawabe, Nobuyoshi Baba, Hiromi Takata, Hisashi Suzuki, Kazuhiro Aihara, Toshiki Fujita
-
Patent number: 7662810Abstract: A 2-arylmethylazetidine carbapenem derivative of formula (I) or a pharmaceutically acceptable salt thereof exhibits a wide spectrum of antibacterial activities against Gram-positive and Gram-negative bacteria and excellent antibacterial activities against resistant bacteria such as methicillinresistant Staphylococcus aureus (MRSA) and quinolone-resistant strains (QRS):Type: GrantFiled: February 24, 2005Date of Patent: February 16, 2010Assignee: Korea Research Institute of Chemical TechnologyInventors: Bong-Jin Kim, Jae-Hak Kim, Jae-Yang Kong, Heeyeong Cho, Young-Ro Choi, Chang-Seob Kim
-
Publication number: 20100029604Abstract: The invention relates to a pharmaceutical composition comprising an ethylene derivatives of tricyclic carbapenems of the general Formula (I) in the form of pure diastereoisomers and in the form of pure geometric isomers or a salt, ester or amide derivate thereof and an antibiotic and the use of this composition as a broad band spectrum ?-lactamase inhibitor.Type: ApplicationFiled: February 13, 2008Publication date: February 4, 2010Inventors: Andrej Prezelj, Uros Urleb, Tomaz Solmajer
-
Publication number: 20090312539Abstract: The present invention provides a process for the preparation of the carbapenem antibiotic of formula (I) or its salt in amorphous form. Formula (I) wherein R represents hydrogen or COOM and M represents hydrogen or sodium.Type: ApplicationFiled: November 20, 2007Publication date: December 17, 2009Applicant: Orchid Chemicals & Pharmaceuticals LimitedInventors: Andrew Gnanaprakasam, Nagappan Arumugam, Palanisamy Senthilkumar Udayampalayam, Pandi Suresh Pandian, Venugopal Sivasankaran, Ganapathy Veeramani, Henry Syril Sudhan, Gollapalli Venkateswara Rao
-
Publication number: 20090299057Abstract: The present invention specially relates to the crystalline form of (4-Nitrobenzyl (4R,5S,6S)-(3-{(3S,5S)-5-[(dimethylamino)carbonyl]-1-[(4-nitrophenoxy)carbonxyl]pyrrolidin-3-yl}thio-6-[(1R)-1-hydorxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0].hept-2-ene-2-carboxylate) of compound Formula I as well as an improved process for preparation of meropenem trihydrate of compound Formula II wherein PNB represents a P-nitro benzyl group and PNZ represents a P-nitrobenzyloxycarbonyl group.Type: ApplicationFiled: October 22, 2008Publication date: December 3, 2009Inventors: Ashwin A. Khemka, Pravin B. Shejul, Amol V. Vyavahare, Dhirendra Kumar Pandey, Sachin N. Shete, Hanumant K. Jadhav, Nitn H. Kadam
-
Publication number: 20090264643Abstract: The present invention relates to a process for the preparation of Meropenem of formula (I) in sterile form and also provides an improved process for the preparation of compound of formula (V), which is an important intermediate in the synthesis of Meropenem.Type: ApplicationFiled: September 15, 2006Publication date: October 22, 2009Inventors: Senthilkumar Surulichamy, Selvakumar Sekar, Pramod Narayan Deshpande, Panchapakesan Ganpathy, Rajendra Janardan Sarangdhar, Syril Sudhan Henry, Sanjay Nivruti Karale, Arvind Atmaram Jangale, Ram Dattatray Kaldate
-
Publication number: 20090216010Abstract: The present invention relates to a crystalline carbapenem compound and produced method thereof. The crystalline carbapenem compound of the present invention is crystalline (4R,5S,6S)-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid and it is characterized by an X-ray powder diffraction pattern of FIG. 2. The crystalline carbapenem compound of the present invention is a new crystalline form and is useful as an antibiotic agent. Furthermore, the crystalline carbapenem compound of the present invention is much more stable than carbapenem compound in a non-crystalline form. Hence, the crystalline carbapenem compound of the present invention is suitable for storage.Type: ApplicationFiled: February 22, 2008Publication date: August 27, 2009Inventors: Wei-Hong Tseng, Yu-Lun Su, Chiung-Yi Yu
-
Patent number: 7534782Abstract: A 1-methylcarbapenem compound ethanolate of the formula (I-1) in the crystalline form that shows main peaks at interplanar spacings d=7.60, 6.69, 6.33, 6.14, 5.15, 4.58 and 4.48 in the X-ray powder diffraction pattern obtained with Cu K? irradiation and a 1-methylcarbapenem compound tetrahydrate of the formula (I-2) in the crystalline form that shows main peaks at interplanar spacings d=11.68, 8.79, 7.53, 6.57, 5.58, 5.37, 3.99 and 3.09 in the X-ray powder diffraction pattern obtained with Cu K? irradiation These compounds are useful for treating or preventing bacterial infections.Type: GrantFiled: February 13, 2006Date of Patent: May 19, 2009Assignee: Sankyo Company, LimitedInventors: Makoto Michida, Yuki Nagao
-
Patent number: 7524952Abstract: The present invention provides a process for efficiently producing a 1?-methylcarbapenem compound for oral administration. The process, which is for producing a 1?-methylcarbapenem compound represented by general formula (2), is characterized by reacting a ?-lactam compound represented by general formula (1) as a starting material with a thiol compound (R3—SH) in the presence of a base and optionally eliminating the protective group R1. In the formulae (1) and (2), R1 denotes a hydrogen atom, a trimethylsilyl group or a triethylsilyl group; R2 denotes an alkyl group having 1 to 10 carbon atoms or a cycloalkyl group having 3 to 10 carbon atoms; R3 denotes an organic group; and R4 denotes hydrogen, a trimethylsilyl group or a triethylsilyl group.Type: GrantFiled: November 13, 2003Date of Patent: April 28, 2009Assignee: Kaneka CorporationInventors: Keita Nishino, Teruyoshi Koga
-
Publication number: 20090082327Abstract: The present application describes deuterium-enriched meropenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 22, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Patent number: 7507814Abstract: The invention provides a novel compound of Formula II which is useful in the preparation of imipenem monohydrate of Formula I, wherein R1 is a p-nitrobenzyl or p-methoxybenzyl group; and R2 and R3 may be identical to or different from each other and are each independently a C1-6alkyl or aryl group, or a derivative thereof, and a process for preparing the compound of Formula II by coupling (5R,6S) p-nitrobenzyl-3-(diphenylphosphono)-6-[(1R)-1-hydroxyethyl]-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate with 2-aminoetahnethiol hydrocloride in the presence of a base, followed by a reaction with a ketone. Further, the invention provides a process for preparing the compound of Formula I by reacting a compound of Formula II with isopropylformimidate or benzylformimidate in the presence of a base, followed by hydrogenation, separation and crystallization.Type: GrantFiled: December 9, 2004Date of Patent: March 24, 2009Assignee: Choongwae Pharm. Co.Inventors: Hyun Seop Bae, Tae Seop Hwang, Chan Yong Ahn, Chang Hoon Oh, Moo Sung Kim
-
Publication number: 20090042819Abstract: The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.Type: ApplicationFiled: February 16, 2006Publication date: February 12, 2009Applicant: NitroMed, Inc.Inventors: James L. Ellis, David S. Garvey, Chia-En Lin
-
Publication number: 20090029964Abstract: An orally administrable antibacterial agent which contains as an active ingredient a carbapenem compound represented by the formula [1] below, wherein R0 represents hydrogen atom or the like; R1 represents C1-C3 alkyl substituted by hydroxyl group or the like; R represents hydrogen atom or a group which regenerates a carboxyl group by hydrolysis in a living body; L represents a single bond, methylene, —OCH2(CO)— or the like; and Het represents a group represented by the following formula [2], wherein m and n independently represent 0 or 1; A and B independently represent methylene, carbonyl or the like; Y represents methylene, ethylene, oxygen atom, —OCH2—, —NRaCH2— (wherein Ra represents hydrogen atom, optionally substituted C1-C4 alkyl group or the like) or the like.Type: ApplicationFiled: March 23, 2006Publication date: January 29, 2009Inventors: Makoto Sunagawa, Akira Sasaki, Takashi Tsukimura
-
Patent number: 7479362Abstract: Aspects of the invention provide a method of controlling the solid-state property of the solid-phase surface or controlling forming reactive region. The method can be attained by using a device for ejecting droplets and a molecule for inclusion in a SAM which can be photo-patterned in a short period of time using low energy UV radiation, that is TV radiation having a relatively long wavelength. The invention can provide monomolecular film that is formed from molecules comprising a structural component (B) which is hydrophobic and/or lipophobic, and a structural component (A) which decomposes when irradiated with UV light having a wavelength in the range 254-400 nm to cleave away a part of the molecule having the structural component (B) leaving a residual hydrophilic structural component (C).Type: GrantFiled: April 28, 2005Date of Patent: January 20, 2009Assignee: Seiko Epson CorporationInventors: Hitoshi Fukushima, Hiroshi Takiguchi, Tatsuya Shimoda, Takashi Masuda, Richard James Bushby, Stephan Evans, J.P. Jeyadevan, Kevin Critchley
-
Publication number: 20090018091Abstract: The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.Type: ApplicationFiled: August 2, 2006Publication date: January 15, 2009Applicant: NITROMED, INC.Inventors: James L. Ellis, David S. Garvey
-
Patent number: 7462712Abstract: The present invention relates to an improved process for the preparation of imipenem comprising reacting a bicyclo ketone precursor of the Formula II, wherein R is a protecting group, with a phosphorohalidate in the presence of a base and a catalytic amount of dialkylaminopyridine.Type: GrantFiled: May 15, 2002Date of Patent: December 9, 2008Assignee: Ranbaxy Laboratories LimitedInventors: Yatendra Kumar, Neera Tewari, Bishwa Prakash Rai
-
Publication number: 20080227768Abstract: Among crystalline forms of compound (I), a 1-methylcarbapenem compound represented by the formula (I) in a crystalline form that shows main peaks in the X-ray powder diffraction pattern obtained with copper K? irradiation.Type: ApplicationFiled: May 12, 2006Publication date: September 18, 2008Inventors: Makoto Michida, Satoshi Kobayashi
-
Publication number: 20080207586Abstract: A novel crystal of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction preferably having main peaks at diffraction angles (2?)=13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees) is provided.Type: ApplicationFiled: February 5, 2008Publication date: August 28, 2008Inventors: Izumi Saitoh, Masayuki Takahira, Toshio Kawakita, Yasuyuki Yoshioka
-
Publication number: 20080139805Abstract: A process for the preparation of carbapenem-type antibacterial agents involving the following reaction: wherein R1 is a C1-C3 alkyl group, n is 0, 1 or 2, A is a C1-C3 alkylene group, L is a leaving group, R3 is a hydrogen atom, a C1-C3 alkyl group or an amino protecting group, and the hydroxyl or carboxyl groups are optionally independently protected. In such process, amine compound (1) or a salt thereof acts as a synthetic intermediate. Such process is a less expensive and highly safe synthetic route for carbapenem-type antibacterial agents suitable for large-scale synthesis.Type: ApplicationFiled: September 19, 2007Publication date: June 12, 2008Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto MICHIDA, Masaki HAYASHI, Satoshi KOBAYASHI
-
Patent number: 7381724Abstract: Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.Type: GrantFiled: May 3, 2006Date of Patent: June 3, 2008Assignee: Sepracor Inc.Inventors: Claude Cotrel, Gerard Roussel
-
Patent number: 7342005Abstract: The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4-alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N—C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n—wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR3—; processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Type: GrantFiled: May 11, 2005Date of Patent: March 11, 2008Assignee: AstraZeneca UK LimitedInventors: Michael John Betts, Gareth Morse Davies, Michael Lingard Swain
-
Patent number: 7332600Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity, which comprises dissolving crude imipenerm in warm water to which some base has been added to obtain a solution, subjecting the resultant solution to activated carbon treatment, and adding an organic solvent to precipitate imipienem monohydrate as a crystalline product.Type: GrantFiled: November 18, 2002Date of Patent: February 19, 2008Assignee: Ranbaxy Laboratories LimitedInventors: Bishwa Prakash Rai, Neera Tewari, Yatendra Kumar
-
Patent number: 7241885Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity comprising the steps of treating an aqueous solution containing imipenem with an organic solvent, wherein the imipenem is not lyophilized; and isolating the pure crystalline imipenem monohydrate from the reaction mixture thereof.Type: GrantFiled: May 20, 2002Date of Patent: July 10, 2007Assignee: Ranbaxy Laboratories LimitedInventors: Yatendra Kumar, Neera Tewari, Ram Chander Aryan, Bishwa Prakash Rai
-
Patent number: 7163936Abstract: 1. A ?-lactam compound of the formula [1]; wherein R1 is a lower alkyl, a lower alkyl substituted by a hydroxy; R2 is a hydrogen, a lower alkyl; X is O, S, NH; m and n are 0 to 4, Y1 is a halogen, cyano, a hydroxy, an amino, a lower alkyloxy, a lower alkylamino, a carboxy, a carbamoyl, a lower alkyl, etc., Y2 is hydrogen, an alkyl, cyano, —C(R3)?NR4 (wherein R3 and R4 are hydrogen, an amino, an alkyl, etc., or R3 and R4 may combine each other together with the nitrogen atom to form a 5- to 7-membered heterocyclic group), or a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof, which has an excellent antibacterial activity against Gram-positive bacteria, especially against MRSA and MRCNS.Type: GrantFiled: November 6, 2001Date of Patent: January 16, 2007Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Makoto Sunagawa, Katsumi Kubota, Masanori Itoh, Erwin Goetschi
-
Patent number: 7145002Abstract: A process for preparing a crystalline, carbapenem monosodium salt of formula IIa: characterized by the steps a) adding about 10 to 30% of an organic solvent to an aqueous solution of the carbapenem, b) cooling the resulting solution to less than ?5° C., c) adjusting the pH using a solution containing an acid in an organic solvent to give the appropriate pH for crystallization, and d) crystallizing the compound by adding methanol, and a C2-5 alcohol at between ?5 and ?25° C.Type: GrantFiled: September 20, 2002Date of Patent: December 5, 2006Assignee: Merck & Co. Inc.Inventors: Karel M. J. Brands, Raymond Cvetovich, Louis S. Crocker, Michael D. Ward, Amar J. Mahajan, Robert M. Wenslow, John M. Williams, Daniel R. Sidler, Charles Orella, Elizabeth S. Fisher, Ronald Jobson
-
Patent number: 7084268Abstract: The present invention provides carbapenem hydrochloride trihydrate crystals, which are chemically stable, easily purified and useful as antimicrobial agents, a process for producing them, and a powdery charged preparation for injection containing them. That is, it provides carbapenem hydrochloride trihydrate crystals having a powdery X-ray diffraction pattern containing lattice distances (d) of 9.0, 4.1 and 2.8 ?, a process for producing them, and a powdery charged preparation for injection containing them.Type: GrantFiled: June 5, 2000Date of Patent: August 1, 2006Assignee: Eisai Co., Ltd.Inventors: Hiroyuki Chiba, Masahiko Tsujii, Astsushi Koiwa, Shin Sakurai, Akio Kayano, Hiroyuki Ishizuka, Hiroyuki Saito, Taiju Nakamura, Ikuo Kushida, Yasuyuki Suzuki, Takako Yoshiba, Kazuhide Ashizawa, Masahiro Sakurai, Eiichi Yamamoto
-
Patent number: 7071330Abstract: A process for synthesizing a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein deprotection is conducted using a prereduced metal catalyst is disclosed.Type: GrantFiled: January 11, 2002Date of Patent: July 4, 2006Inventors: John M. Williams, Renato Skerlj
-
Patent number: 7041836Abstract: The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4-alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4-alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N—C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n— wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR3—. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Type: GrantFiled: November 14, 2002Date of Patent: May 9, 2006Assignee: AstraZeneca UK LimitedInventors: Michael John Betts, Gareth Morse Davies, Michael Lingard Swain
-
Patent number: 7041660Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I-1), (I-2) or (I-3) The crystalline forms of the 1-methylcarbapenem derivative exhibit excellent antibiotic activity against various bacterial strains and sufficient stability for practical use.Type: GrantFiled: July 23, 2003Date of Patent: May 9, 2006Assignee: Sankyo Company, LimitedInventors: Isao Kawamoto, Yasuo Shimoj, Hiroshi Fukuhara
-
Patent number: 7034150Abstract: A process for the preparation of a carbapenem antibacterial compound of the following formula (4) having a 1-alkylpyrrolidine structure or a salt thereof, a useful synthetic intermediate of the following formula (1) or a salt thereof, and a process for the preparation thereof: wherein R1 represents a C1–C3 alkyl group, R2 and R3 each independently represents a hydrogen atom or an organic residue or R2 and R3 together with the nitrogen atom they are attached to form a ring.Type: GrantFiled: May 14, 2003Date of Patent: April 25, 2006Assignee: Sankyo Company, LimitedInventors: Katsuhiko Fujimoto, Takashi Kasai
-
Patent number: 7022841Abstract: The present invention relates to a process for reducing the levels of organic solvents to pharmaceutically acceptable levels in thermally unstable crystalline carbapenem solids represented by formula I: or a salt thereof, wherein R1 and R2, are the same or different, and are selected from H, alkyl, aryl, and heteroaryl, comprising washing a carbapenem solid containing organic solvent with an organic solvent containing water; and using vacuum and/or inert gas (hydrated or dry) at low temperature to produce a compound of formula I containing pharmaceutically acceptable levels of organic solvents, wherein the water content of the crystalline carbapenem solid, correcting for organic solvents, is maintained at about 13% to about 25% during the process.Type: GrantFiled: September 20, 2002Date of Patent: April 4, 2006Assignee: Merck & Co. Inc.Inventors: Raymond Cvetovich, Robert Wenslow, John M. Williams, Daniel Sidler, Louis Crocker, Hsien-Hsin Tung, Brian K. Johnson, Joseph Kukura, II, Ulf Dolling
-
Patent number: 7001897Abstract: A 1-methylcarbapenem compound represented by the formula (I): having antibacterial activity, pharmacologically acceptable esters or salts thereof and pharmaceutical compositions (particularly antibacterial agents) containing them as an active ingredient are described. In addition, the invention includes the use of these compounds, ester derivatives or salts for the manufacture of pharmaceutical compositions, or a method for the prevention or treatment of diseases (particularly bacterial infections) by administering a pharmacologically effective amount of the compounds, ester derivatives or salts to warm-blooded animals (particularly human beings).Type: GrantFiled: May 15, 2003Date of Patent: February 21, 2006Assignee: Sankyo Company, LimitedInventors: Yoshiyuki Kobayashi, Tsuyoshi Shinozuka, Osamu Kanno
-
Patent number: 6924279Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof. The crystalline forms of the 1-methylcarbapenem derivative exhibit excellent antibiotic activity against various bacterial strains and sufficient stability for practical use.Type: GrantFiled: January 27, 2003Date of Patent: August 2, 2005Assignee: Sankyo Company, LimitedInventors: Isao Kawamoto, Yasuo Shimoji, Hiroshi Fukuhara
-
Publication number: 20040242865Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity.Type: ApplicationFiled: June 17, 2004Publication date: December 2, 2004Inventors: Yatendra Kumar, Neera Tewari, Ram Chander Aryan, Bishwa Prakash Rai
-
Publication number: 20040235817Abstract: A process for preparing a crystalline, carbapenem monosodium salt of formula IIa: 1Type: ApplicationFiled: January 27, 2004Publication date: November 25, 2004Inventors: Karel M. J. Brands, Raymond Cvetovich, Louis S Crocker, Michael D Ward, Amar J Mahajan, Robert M Wenslow, John M Williams, Daniel R Sidler, Charles Orella, Elizabeth S Fisher
-
Publication number: 20040220168Abstract: The present invention relates to an improved, cost effective and industrially advantageous process for the preparation of imipenem.Type: ApplicationFiled: June 16, 2004Publication date: November 4, 2004Inventors: Yatendra Kumar, Neera Tewari, Bishwa Prakash Rai
-
Publication number: 20040198973Abstract: A process for the preparation of carbapenem antibiotics, which is free from the two disadvantages: (1) use of column chromatography and (2) recovery of a difficulty soluble salt and by which the objective compounds can be efficiently prepared in a short period. Specifically, a process for the preparation of compounds represented by the general formula (IV), salts thereof, or hydrates of both, characterized by reacting a compound represented by the general formula (I) with a compound represented by the general formula (II): X—H (wherein X is a member selected from the group consisting of substituents represented by the formulae (X-1) to (X-8)) to thereby obtain a compound represented by the general formula (III) or salt thereof, converting the compound (III) or salt thereof into a compound represented by the general formula (IV) or a salt thereof through the removal of the protecting group (R3), and purifying the compound (IV) or salt thereof by crystallization.Type: ApplicationFiled: February 13, 2004Publication date: October 7, 2004Inventors: Tsujii Masahiko, Hiroyuki Ishizuka, Atsushi Koiwa
-
Publication number: 20040176350Abstract: A carbapenem compound represented by the formula (I′): 1Type: ApplicationFiled: November 21, 2003Publication date: September 9, 2004Inventor: Hiroshi Matsui
-
Publication number: 20040176351Abstract: The present invention relates to a process for reducing the levels of organic solvents to pharmaceutically acceptable levels in thermally unstable crystalline carbapenem solids represented by formula I: 1Type: ApplicationFiled: January 27, 2004Publication date: September 9, 2004Inventors: Raymond Cvetovich, Robert Wenslow, John Williams, Daniel Sidler, Louis Crocker, Hsien-Hsin Tung, Brian K Johnson, Joseph Kukura, Ulf Dolling
-
Publication number: 20040132993Abstract: Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.Type: ApplicationFiled: November 25, 2003Publication date: July 8, 2004Inventor: B. Vithal Shetty
-
Publication number: 20040132668Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 23, 2003Publication date: July 8, 2004Applicant: SANKYO COMPANY, LIMITEDInventors: Isao Kawamoto, Yasuo Shimoji, Hiroshi Fukuhara
-
Publication number: 20040102433Abstract: 1.Type: ApplicationFiled: May 8, 2003Publication date: May 27, 2004Inventors: Makoto Sunagawa, Katsumi Kubota, Masanori Itoh, Erwin Goetschi
-
Publication number: 20040063683Abstract: Carbapenem compounds having a substituted phenyl or a substituted thienyl directly attached to the 3-position of carbapenem nucleus as represented by the formula: 1Type: ApplicationFiled: June 27, 2003Publication date: April 1, 2004Inventors: Makoto Sunagawa, Akira Sasaki
-
Publication number: 20040063930Abstract: A novel process for the removal of impurities from clavulanic acid using a selective adsorption material, in particular a molecularly imprinted polymer. Novel selective adsorption materials suitable for the process, and a process for the preparation of such selective adsorption materials, are also disclosed.Type: ApplicationFiled: October 10, 2003Publication date: April 1, 2004Inventors: Klaus Mosbach, Lei Ye, Yihua Yu
-
Publication number: 20040063931Abstract: A process for synthesizing a compound represented by formula I: 1Type: ApplicationFiled: July 16, 2003Publication date: April 1, 2004Inventors: John M. William, Renato Skerlj
-
Publication number: 20040054167Abstract: The present invention relates to a cost effective and commercially viable process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (Imipenem monohydrate) of Formula I.Type: ApplicationFiled: September 18, 2003Publication date: March 18, 2004Inventors: Yatendra Kumar, Neera Tewari, Ran Chander Aryan, Bishwa Prakash Rai, Seema Ahuja
-
Patent number: RE40794Abstract: A process for preparing a crystalline, carbapenem monosodium salt of formula IIa: characterized by the steps a) adding about 10 to 30% of an organic solvent to an aqueous solution of the carbapenem, b) cooling the resulting solution to less than ?5° C., c) adjusting the pH using a solution containing an acid in an organic solvent to give the appropriate pH for crystallization, and d) crystallizing the compound by adding methanol, and a C2-5 alcohol at between ?5 and ?25° C.Type: GrantFiled: September 20, 2002Date of Patent: June 23, 2009Assignee: Merck & Co., Inc.Inventors: Karel M. J. Brands, Raymond Cvetovich, Louis S. Crocker, Michael D. Ward, Amar J. Mahajan, Robert M. Wenslow, John M. Williams, Daniel R. Sidler, Charles Orella, Elizabeth S. Fisher, Ronald Jobson